Lipella Pharmaceuticals (NASDAQ:LIPO) announced that the U.S. Patent and Trademark Office (USPTO), has issued a patent for its proprietary liposomal delivery platform today.
Lipella reports that the patent protects its method of using metastable liposomes to deliver therapeutic agents, securing broad intellectual property rights for the company’s drug delivery platform. This patent provides extended market exclusivity for Lipella’s two lead clinical assets, LP-10 and LP-310, which are currently in Phase 2 clinical trials.
“We believe our proprietary liposomal drug delivery platform holds significant potential to enhance efficacy and tolerability across various therapeutic areas, including oncology, cancer survivorship and immunotherapy. This platform offers a safer, more effective way to administer therapeutics like tacrolimus, providing patients with targeted treatment options that minimize side effects,” said Dr. Michael Chancellor, CMO of Lipella.
“The official issuance of this strategically important patent marks a pivotal advancement for Lipella, strengthening our intellectual property portfolio and supporting our commitment to advancing treatments for critical conditions such as hemorrhagic cystitis and oral lichen planus,” added Dr. Chancellor.
